Meeting Coverage

Meeting Coverage

Updates from major medical meetings in the field of hematology/oncology

On location

Manipulating Natural Killer Cells to Fight Myeloma

Using cord blood–derived natural killer (NK) cells in hematopoietic cell transplantation (HCT) appears to enhance the effectiveness of the transplant in patients with myeloma,...
On location

Nelarabine and Standard Chemotherapy Improves Disease-Free Survival in Pediatric T-Cell Malignancies

Adding nelarabine to a standard chemotherapy regimen improved disease-free survival (DFS) in children and young adults with T-cell acute lymphocytic leukemia (TALL), compared with...
On location

Results from ARROW Trial Point to Once-Weekly Carfilzomib Dosing

Carfilzomib is approved on a twice-weekly dosing schedule for the treatment of relapsed or refractory multiple myeloma (MM), but in the phase III ARROW...
On location

High Rates of Response, Survival With Ibrutinib Plus Rituximab in Waldenström Macroglobulinemia

Treatment with a combination of ibrutinib and rituximab improved progression-free survival (PFS) over rituximab alone in patients with Waldenström macroglobulinemia (WM), according to results...
On location

Venetoclax, Carfilzomib, Dexamethasone Combo Appears Well Tolerated in Relapsed/Refractory MM

In an ongoing phase II study, the addition of the BCL2 inhibitor venetoclax to the combination of carfilzomib and dexamethasone did not raise any...

Nilotinib Improves Prognosis in Elderly Patients with Ph+ ALL

For the difficult-to-treat elderly population (aged ≥55 years) with Philadelphia chromosome positive (Ph+) acute lymphocytic leukemia (ALL), combining age-adapted, low-intensity chemotherapy with nilotinib is...

2014 ASH Annual Meeting Program Preview: A Discussion with Program Co-Chairs

Now that the “ASH Dash” to submit abstracts is finished, we can look forward to taking advantage of everything this year’s annual meeting in...
Advertisement

Current Issue

June 2019, Volume 5, Issue 7

This issue features a debate about new treatment options for beta-thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more.